


**Claims**

1. A compound of formula (1):



wherein:

A is phenylene or heteroarylene;

n is 0, 1, or 2;

m is 0, 1, or 2;

R<sup>1</sup> is independently selected from halo, nitro, cyano, hydroxy, carboxy, carbamoyl, *N*-C<sub>1-4</sub>alkylcarbamoyl, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>carbamoyl, sulphamoyl, *N*-C<sub>1-4</sub>alkylsulphamoyl,


*N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>sulphamoyl, -S(O)<sub>b</sub>C<sub>1-4</sub>alkyl (wherein b is 0, 1, or 2), C<sub>1-4</sub>alkyl, C<sub>2-4</sub>alkenyl, C<sub>2-4</sub>alkynyl, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkanoyl, C<sub>1-4</sub>alkanoyloxy, hydroxyC<sub>1-4</sub>alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, and trifluoromethoxy; or

when n is 2, the two R<sup>1</sup> groups, together with the carbon atoms of A to which they are attached, may form a 4- to 7-membered ring, optionally containing 1 or 2 heteroatoms independently selected from O, S, and N, and optionally being substituted with one or two methyl groups;

R<sup>4</sup> is independently selected from hydrogen, halo, nitro, cyano, hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, trifluoromethoxy, carboxy, carbamoyl, C<sub>1-4</sub>alkyl, C<sub>2-4</sub>alkenyl, C<sub>2-4</sub>alkynyl, C<sub>1-4</sub>alkoxy, and C<sub>1-4</sub>alkanoyl;

r is 1 or 2;

when r is 1 the group




is a substituent on carbon (2);


when  $r$  is 2 (thereby forming a six membered ring) the same group is a substituent on carbon (2) or on carbon (3);

$Y$  is  $-NR^2R^3$  or  $-OR^3$ ;

$R^2$  and  $R^3$  are independently selected from hydrogen, hydroxy,  $C_{1-4}$ alkoxy,  $C_{1-4}$ alkanoyl, carbamoyl,  $C_{3-7}$ cycloalkyl (optionally substituted with 1 or 2 hydroxy groups), cyano( $C_{1-4}$ )alkyl, heterocyclyl, aryl,  $C_{1-4}$ alkyl [optionally substituted with 1 or 2  $R^8$  groups],  $-COR^8$ ,  $-SO_bR^8$  (wherein  $b$  is 0, 1, or 2), and groups of the formulae B and B'



(B)



(B')

wherein  $y$  is 0 or 1,  $t$  is 0, 1, 2, or 3 and  $u$  is 1 or 2; provided that the hydroxy group is not a substituent on the ring carbon adjacent to the ring oxygen; or

wherein  $NR^2R^3$  may form a 4- to 7-membered saturated, partially saturated, or unsaturated ring, optionally containing 1, 2, or 3 additional heteroatoms independently selected from N, O, and S, wherein any  $-CH_2-$  may optionally be replaced by  $-C(=O)-$ , and any N or S atom may optionally be oxidized to form an N-oxide, SO, or  $SO_2$  group respectively, and wherein the ring is optionally substituted with 1 or 2 substituents independently selected from halo, cyano,  $C_{1-4}$ alkyl, hydroxy,  $C_{1-4}$ alkoxy, and  $C_{1-4}alkylS(O)_b-$  (wherein  $b$  is 0, 1, or 2);

$R^8$  is independently selected from hydrogen, hydroxy,  $C_{1-4}$ alkyl,  $C_{2-4}$ alkenyl,  $C_{1-4}$ alkoxy, cyano( $C_{1-4}$ )alkyl, amino( $C_{1-4}$ )alkyl [optionally substituted on nitrogen with 1 or 2 groups selected from  $C_{1-4}$ alkyl, hydroxy, hydroxy( $C_{1-4}$ )alkyl, dihydroxy( $C_{1-4}$ )alkyl,  $-CO_2C_{1-4}$ alkyl, aryl, and aryl( $C_{1-4}$ )alkyl], halo( $C_{1-4}$ )alkyl, dihalo( $C_{1-4}$ )alkyl, trihalo( $C_{1-4}$ )alkyl, hydroxy( $C_{1-4}$ )alkyl, dihydroxy( $C_{1-4}$ )alkyl,  $C_{1-4}$ alkoxy $C_{1-4}$ alkoxy,  $C_{1-4}$ alkoxy $C_{1-4}$ alkyl, hydroxy $C_{1-4}$ alkoxy, 5- and 6-membered cyclic acetals and mono- and di-methyl derivatives thereof, aryl, heterocyclyl, (heterocyclyl) $C_{1-4}$ alkyl,  $C_{3-7}$ cycloalkyl (optionally substituted with 1 or 2 hydroxy groups,

C<sub>1-4</sub>alkyl, or -C(O)OC<sub>1-4</sub>alkyl), C<sub>1-4</sub>alkanoyl, C<sub>1-4</sub>alkylS(O)<sub>b</sub>- (wherein b is 0, 1, or 2), C<sub>3-6</sub>cycloalkylS(O)<sub>b</sub>- (wherein b is 0, 1, or 2), arylS(O)<sub>b</sub>- (wherein b is 0, 1, or 2), heterocyclylS(O)<sub>b</sub>- (wherein b is 0, 1, or 2), benzylS(O)<sub>b</sub>- (wherein b is 0, 1, or 2), C<sub>1-4</sub>alkylS(O)<sub>c</sub>(C<sub>1-4</sub>)alkyl (wherein c is 0, 1, or 2), -N(OH)CHO, -C(=N-OH)NH<sub>2</sub>, -C(=N-OH)NHC<sub>1-4</sub>alkyl, -C(=N-OH)N(C<sub>1-4</sub>alkyl)<sub>2</sub>, -C(=N-OH)NHC<sub>3-6</sub>cycloalkyl, -C(=N-OH)N(C<sub>3-6</sub>cycloalkyl)<sub>2</sub>, -COCOOR<sup>9</sup>, -C(O)N(R<sup>9</sup>)(R<sup>10</sup>), -NHC(O)R<sup>9</sup>, -C(O)NHSO<sub>2</sub>(C<sub>1-4</sub>alkyl), -NHSO<sub>2</sub>R<sup>9</sup>, (R<sup>9</sup>)(R<sup>10</sup>)NSO<sub>2</sub>-, -COCH<sub>2</sub>OR<sup>11</sup>, (R<sup>9</sup>)(R<sup>10</sup>)N-, -COOR<sup>9</sup>, -CH<sub>2</sub>OR<sup>9</sup>, -CH<sub>2</sub>COOR<sup>9</sup>, -CH<sub>2</sub>OCOR<sup>9</sup>, -CH<sub>2</sub>CH(CO<sub>2</sub>R<sup>9</sup>)OH, -CH<sub>2</sub>C(O)NR<sup>9</sup>R<sup>10</sup>, -(CH<sub>2</sub>)<sub>w</sub>CH(NR<sup>9</sup>R<sup>10</sup>)CO<sub>2</sub>R<sup>9'</sup> (wherein w is 1, 2 or 3), and -(CH<sub>2</sub>)<sub>w</sub>CH(NR<sup>9</sup>R<sup>10</sup>)CO(NR<sup>9'</sup>R<sup>10'</sup>) (wherein w is 1, 2, or 3) ;

R<sup>9</sup>, R<sup>9'</sup>, R<sup>10</sup>, and R<sup>10'</sup> are independently selected from hydrogen, hydroxy, C<sub>1-4</sub>alkyl (optionally substituted with 1 or 2 R<sup>13</sup>), C<sub>2-4</sub>alkenyl, C<sub>3-7</sub>cycloalkyl (optionally substituted with 1 or 2 hydroxy groups), cyano(C<sub>1-4</sub>)alkyl, trihaloalkyl, aryl, heterocyclyl, heterocyclyl(C<sub>1-4</sub>alkyl), and -C(=O)O(C<sub>1-4</sub>)alkyl; or

R<sup>9</sup> and R<sup>10</sup> together with the nitrogen to which they are attached, or R<sup>9'</sup> and R<sup>10'</sup> together with the nitrogen to which they are attached, form a 4- to 6-membered ring where the ring is optionally substituted on carbon with 1 or 2 substituents independently selected from oxo, hydroxy, carboxy, halo, nitro, cyano, carbonyl, C<sub>1-4</sub>alkoxy, and heterocyclyl; or the ring may be optionally substituted on two adjacent carbons with -O-CH<sub>2</sub>-O- to form a cyclic acetal wherein one or both of the hydrogens of the -O-CH<sub>2</sub>-O- group may be replaced by a methyl;

R<sup>13</sup> is selected from halo, trihalomethyl, and C<sub>1-4</sub>alkoxy; and

R<sup>11</sup> is independently selected from hydrogen, C<sub>1-4</sub>alkyl, and hydroxyC<sub>1-4</sub>alkyl; or a pharmaceutically acceptable salt or prodrug thereof.

2. A compound of claim 1, wherein:

R<sup>2</sup> and R<sup>3</sup> are independently selected from hydrogen, hydroxy, C<sub>1-4</sub>alkyl [optionally substituted with 1 or 2 R<sup>8</sup> groups], C<sub>3-7</sub>cycloalkyl (optionally substituted with 1 or 2 hydroxy groups), cyano(C<sub>1-4</sub>)alkyl, phenyl, morpholino, morpholinyl, piperidino, piperidyl, pyridyl, pyranyl, pyrrolyl, imidazolyl, thiazolyl, thienyl, thiadiazolyl, piperazinyl, isothiazolidinyl, 1,3,4-triazolyl, tetrazolyl, pyrrolidinyl, thiomorpholino, pyrrolinyl, homopiperazinyl, 3,5-dioxapiperidinyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrazolyl, pyrazolinyl, isoxazolyl, 4-oxopyridyl, 2-oxopyrrolidyl, 4-oxothiazolidyl, furyl, thienyl, oxazolyl, 1,3,4-oxadiazolyl, and 1,2,4-oxadiazolyl,

tetrahydrothiopyranyl, 1-oxotetrahydrothiopyranyl, 1,1-dioxotetrahydrothiopyranyl, -COR<sup>8</sup>, and -SO<sub>b</sub>R<sup>8</sup> (wherein b is 0, 1, or 2);

R<sup>8</sup> is independently selected from hydrogen, hydroxy, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkoxyC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxyC<sub>1-4</sub>alkoxy, hydroxyC<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkyl, , amino(C<sub>1-4</sub>)alkyl [optionally substituted on nitrogen with 1 or 2 groups selected from C<sub>1-4</sub>alkyl, hydroxy(C<sub>1-4</sub>)alkyl, dihydroxy(C<sub>1-4</sub>)alkyl, -CO<sub>2</sub>C<sub>1-4</sub>alkyl, aryl, and aryl(C<sub>1-4</sub>)alkyl], C<sub>2-4</sub>alkenyl, C<sub>3-7</sub>cycloalkyl (optionally substituted with -C(O)OC<sub>1-4</sub>alkyl), 5- and 6-membered cyclic acetals and mono- and di-methyl derivatives thereof, halo(C<sub>1-4</sub>)alkyl, dihalo(C<sub>1-4</sub>)alkyl, trihalo(C<sub>1-4</sub>)alkyl, hydroxy(C<sub>1-4</sub>)alkyl, dihydroxy(C<sub>1-4</sub>)alkyl, cyano(C<sub>1-4</sub>)alkyl, heterocyclyl, heterocyclylC<sub>1-4</sub>alkyl, aryl, C<sub>1-4</sub>alkylS(O)<sub>b</sub>- (wherein b is 0, 1, or 2), C<sub>3-6</sub>cycloalkylS(O)<sub>b</sub>- (wherein b is 0, 1, or 2), arylS(O)<sub>b</sub>- (wherein b is 0, 1, or 2), heterocyclylS(O)<sub>b</sub>- (wherein b is 0, 1, or 2), benzylS(O)<sub>b</sub>- (wherein b is 0, 1, or 2), C<sub>1-4</sub>alkylS(O)<sub>c</sub>(C<sub>1-4</sub>)alkyl (wherein c is 0, 1, or 2), -CH<sub>2</sub>CH(NR<sup>9</sup>R<sup>10</sup>)CO(NR<sup>9</sup>R<sup>10</sup>), -CH<sub>2</sub>OR<sup>9</sup>, (R<sup>9</sup>)(R<sup>10</sup>)N-, -COOR<sup>9</sup>, -CH<sub>2</sub>COOR<sup>9</sup>, -C(O)N(R<sup>9</sup>)(R<sup>10</sup>), -CH<sub>2</sub>CH(CO<sub>2</sub>R<sup>9</sup>)OH, -CH<sub>2</sub>CONR<sup>9</sup>R<sup>10</sup>, -CH<sub>2</sub>CH(NR<sup>9</sup>R<sup>10</sup>)CO<sub>2</sub>R<sup>9</sup>, and -CH<sub>2</sub>OCOR<sup>9</sup>;

R<sup>9</sup>, R<sup>9'</sup>, R<sup>10</sup>, and R<sup>10'</sup> are independently selected from hydrogen, C<sub>1-4</sub>alkyl (optionally substituted with 1 or 2 R<sup>13</sup>), C<sub>3-7</sub>cycloalkyl (optionally substituted with 1 or 2 hydroxy groups), -C(=O)O<sup>t</sup>Bu, C<sub>2-4</sub>alkenyl, cyano(C<sub>1-4</sub>)alkyl, phenyl (optionally substituted with 1 or 2 groups selected from nitro, halo, hydroxy, and cyano); or

R<sup>9</sup> and R<sup>10</sup> together with the nitrogen to which they are attached, or R<sup>9'</sup> and R<sup>10'</sup> together with the nitrogen to which they are attached, form a 4- to 6-membered ring where the ring is optionally substituted on carbon with 1 or 2 substituents independently selected from oxo, hydroxy, carboxy, halo, nitro, cyano, carbonyl, and C<sub>1-4</sub>alkoxy; or the ring may be optionally substituted on two adjacent carbons with -O-CH<sub>2</sub>-O- to form a cyclic acetal wherein one or both of the hydrogens of the -O-CH<sub>2</sub>-O- group may be replaced by a methyl; and

R<sup>13</sup> is selected from halo, trihalomethyl, and C<sub>1-4</sub>alkoxy; or a pharmaceutically acceptable salt or an in-vivo hydrolysable ester thereof.

3. A compound of claim 1, wherein:

R<sup>2</sup> and R<sup>3</sup> are independently selected from hydrogen, C<sub>1-4</sub>alkyl [optionally substituted with 1 or 2 R<sup>8</sup> groups], -COR<sup>8</sup> and -SO<sub>b</sub>R<sup>8</sup> (wherein b is 0, 1, or 2);


$R^8$  is independently selected from hydrogen, hydroxy,  $C_{1-4}$ alkoxy,  $C_{1-4}$ alkoxy $C_{1-4}$ alkyl,  $C_{1-4}$ alkyl, amino( $C_{1-4}$ )alkyl [optionally substituted on nitrogen with 1 or 2 groups selected from  $C_{1-4}$ alkyl, hydroxy( $C_{1-4}$ )alkyl, dihydroxy( $C_{1-4}$ )alkyl,  $-CO_2C_{1-4}$ alkyl, phenyl, and aryl( $C_{1-4}$ )alkyl],  $C_{2-4}$ alkenyl,  $C_{3-7}$ cycloalkyl (optionally substituted with  $-C(O)OC_{1-4}$ alkyl), 5- and 6-membered cyclic acetals and mono- and di-methyl derivatives thereof, halo( $C_{1-4}$ )alkyl, trihalo( $C_{1-4}$ )alkyl, hydroxy( $C_{1-4}$ )alkyl, dihydroxy( $C_{1-4}$ )alkyl, cyano( $C_{1-4}$ )alkyl, furyl (optionally substituted on carbon with 1 or 2 nitro groups), thienyl (optionally substituted on carbon with 1 or 2 nitro groups), morpholino, furyl( $C_{1-4}$ )alkyl (wherein furyl is optionally substituted on carbon with 1 or 2 nitro groups), thienyl( $C_{1-4}$ )alkyl (wherein thienyl is optionally substituted on carbon by 1 or 2 nitro groups), 1,2,4-oxadiazolyl, tetrazolyl, imidazolyl, pyrrolidinyl, piperidyl, pyridyl, tetrahydrofuryl, tetrahydropyranyl, 1-oxo-tetrahydrothiopyranyl, tetrahydrothienyl, phenyl (optionally substituted with 1 or 2 groups selected from nitro, halo, cyano, hydroxy, and  $C_{1-4}$ alkyl), pyrazinyl, piperazinyl, 4-methylpiperazino,  $C_{1-4}$ alkylS(O)<sub>b</sub>- (wherein b is 0, 1, or 2),  $C_{3-6}$ cycloalkylS(O)<sub>b</sub>- (wherein b is 0, 1, or 2), arylS(O)<sub>b</sub>- (wherein b is 0, 1, or 2), heterocyclylS(O)<sub>b</sub>- (wherein b is 0, 1, or 2),  $-CH_2CH(NR^9R^{10})CO(NR^9R^{10})$ ,  $-CH_2OR^9$ ,  $(R^9)(R^{10})N-$ ,  $-COOR^9$ ,  $-CH_2COOR^9$ ,  $-C(O)N(R^9)(R^{10})$ ,  $-CH_2CH(CO_2R^9)OH$ ,  $-CH_2CONR^9R^{10}$ ,  $-CH_2CH(NR^9R^{10})CO_2R^9$ , and  $-CH_2OCOR^9$ ; and

$R^9$ ,  $R^9$ ,  $R^{10}$ , and  $R^{10}$  are independently selected from hydrogen,  $C_{1-4}$ alkyl (optionally substituted with 1 or 2 hydroxy groups),  $C_{2-4}$ alkenyl, and phenyl (optionally substituted with 1 or 2 groups selected from nitro, halo, hydroxy, and cyano);

or a pharmaceutically acceptable salt or an in-vivo hydrolysable ester thereof.

4. A compound of claim 1, wherein Y is  $NR^2R^3$ , or a pharmaceutically acceptable salt or an in-vivo hydrolysable ester thereof.
5. A compound of claim 1, wherein Y is  $OR^3$ , or a pharmaceutically acceptable salt or an in-vivo hydrolysable ester thereof.
6. A compound of claim 1, wherein m is 1 and  $R^4$  is chlorine, or a pharmaceutically acceptable salt or an in-vivo hydrolysable ester thereof.

7. A compound of claim 1, wherein A is phenylene, or a pharmaceutically acceptable salt or an in-vivo hydrolysable ester thereof.
8. A compound of claim 1, wherein A is heteroarylene, or a pharmaceutically acceptable salt or an in-vivo hydrolysable ester thereof.
9. A compound of claim 1, which is a compound of formula (1A):



or a pharmaceutically acceptable salt or an in-vivo hydrolysable ester thereof.

10. A compound of claim 1, selected from:
- 5-chloro-2-[*N*-(1-hydroxyindan-2-yl)carbamoyl]indole;
  - 5-chloro-*N*-{(1*R*,2*R*)-1-[(methanesulfonyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;
  - N*-{(1*R*\*, 2*R*\*)-1-[(2-carboxyacetyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-chloroindole-2-carboxamide;
  - 5-chloro-*N*-{(1*R*,2*R*)-1-[(3-methoxypropanoyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;
  - N*-[(1*R*,2*R*)-1-(acetlamino)-2,3-dihydro-1*H*-inden-2-yl]-5-chloro-1*H*-indole-2-carboxamide;
  - 5-chloro-*N*-[(1*R*,2*R*)-1-(*tert*-butoxycarbonylaminoacetamido)-2,3-dihydro-1*H*-inden-2-yl]-1*H*-indole-2-carboxamide;
  - N*-[(1*R*,2*R*)-1-{[3-(*tert*-butoxycarbonylamino)-4-oxopentanoyl]amino}-2,3-dihydro-1*H*-inden-2-yl]-5-chloro-1*H*-indole-2-carboxamide;
  - N*-{(1*R*,2*R*)-1-[(2-carbamoylacetyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-chloroindole-2-carboxamide;
  - N*-{(1*R*,2*R*)-1-[(2-carboxyacetyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-chloroindole-2-carboxamide;

5-chloro-*N*-{(1*R*,2*R*)-1-[(hydroxyacetyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;  
 2-chloro-*N*-{(1*R*,2*R*)-1-[[3-hydroxy-2-(hydroxymethyl)propanoyl]amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;  
*N*-{(1*R*,2*R*)-1-[(3*R*)-3-amino-3-carbamoylpropanoyl]amino]-2,3-dihydro-1*H*-inden-2-yl}-5-chloroindole-2-carboxamide;  
*N*-{(1*R*,2*R*)-1-[(aminoacetyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-chloro-1*H*-indole-2-carboxamide;  
 5-chloro-*N*-{(1*S*,2*S*)-1-[(methylsulfonyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;  
 5-chloro-*N*-{1-[(hydroxyacetyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;  
 5-chloro-*N*-[(1*R*,2*R*)-1-({[(2-hydroxyethyl)(methyl)amino]acetyl}amino)-2,3-dihydro-1*H*-inden-2-yl]-1*H*-indole-2-carboxamide;  
 5-chloro-*N*-[(1*R*,2*R*)-1-({[(2-hydroxyethyl)(phenylmethyl)amino]acetyl}amino)-2,3-dihydro-1*H*-inden-2-yl]-1*H*-indole-2-carboxamide;  
 5-chloro-*N*-{(1*R*,2*R*)-1-{{[(3-hydroxypiperidin-1-yl)acetyl]amino}-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;  
 5-chloro-*N*-{(1*R*,2*R*)-1-{{[(3-hydroxypyrrolidin-1-yl)acetyl]amino}-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;  
*N*-[(1*R*,2*R*)-1-({[bis(2-hydroxyethyl)amino]acetyl}amino)-2,3-dihydro-1*H*-inden-2-yl]-5-chloro-1*H*-indole-2-carboxamide;  
*N*-{1-[(aminoacetyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-chloro-1*H*-indole-2-carboxamide;  
*N*-{1-[(3*S*)-3-amino-3-carboxypropanoyl]amino]-2,3-dihydro-1*H*-inden-2-yl}-5-chloroindole-2-carboxamide;  
 5-chloro-*N*-{(1*R*,2*R*)-1-{{[(chloromethyl)sulfonyl]amino}-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;  
 5-chloro-*N*-(1-{{[(trifluoromethyl)sulfonyl]amino}-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;  
 5-chloro-*N*-{1-[(cyanomethyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;  
 5-chloro-*N*-{(1*R*,2*R*)-1-[(1*H*-tetrazol-5-ylmethyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-1*H*-indole-2-carboxamide;

*N*-{(1*R*,2*R*)-1-[(2-amino-2-oxoethyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-chloro-1*H*-indole-2-carboxamide;  
*N*-[(1*R*,2*R*)-1-(carboxymethylamino)-2,3-dihydro-1*H*-inden-2-yl]-5-chloroindole-2-carboxamide;  
*N*-{(1*S*,2*S*)-1-[acetyl(2-thienylmethyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-chloro-1*H*-indole-2-carboxamide;  
*N*-{(1*S*,2*S*)-1-[*N*-acetyl-*N*-(carboxymethyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-chloroindole-2-carboxamide;  
*N*-[(1*S*,2*S*)-1-{*N*-acetyl-*N*-[2-(ethoxycarbonyl)cycloprop-1-ylmethyl]amino}-2,3-dihydro-1*H*-inden-2-yl]-5-chloroindole-2-carboxamide;  
*N*-{(1*R*,2*R*)-1-[*N*-acetyl-*N*-(carboxymethyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-chloroindole-2-carboxamide;  
*N*-{(1*R*,2*R*)-1-[bis-(carboxymethyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-chloroindole-2-carboxamide;  
*N*-{(1*R*,2*R*)-1-[Acetyl(2-amino-2-oxoethyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-chloro-1*H*-indole-2-carboxamide;  
*N*-{(1*R*,2*R*)-1-[*N*-(2-acetoxyacetyl)-*N*-(carboxymethyl)amino]-2,3-dihydro-1*H*-inden-2-yl}-5-chloroindole-2-carboxamide;  
5-chloro-*N*-[(1*R*,2*R*)-1-(2,5-dioxomorpholin-4-yl)-2,3-dihydro-1*H*-inden-2-yl]-1*H*-indole-2-carboxamide; and  
5-chloro-*N*-[(1*R*,2*R*)-1-{[(2*R*)-2,3-dihydroxypropyl]amino}-2,3-dihydro-1*H*-inden-2-yl]-1*H*-indole-2-carboxamide;  
or a pharmaceutically acceptable salt or an in-vivo hydrolysable ester thereof.

11. A pharmaceutical composition which comprises a compound of claim 1, or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof in association with a pharmaceutically acceptable diluent or carrier.

12. A method for the treatment of type 2 diabetes, insulin resistance, syndrome X, hyperinsulinaemia, hyperglucagonaemia, cardiac ischaemia or obesity in a warm-blooded animal, comprising administering a compound of claim 1, or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof.




100663-1P US

13. A method for the treatment of type 2 diabetes in a warm-blooded animal, comprising administering a compound of claim 1, or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof.


14. A process for the preparation of a compound of claim 1, which process comprises:

reacting an acid of the formula (2)



(2)

or an activated derivative thereof; with an amine of formula (3)



(3)

and thereafter if necessary

- i) converting a compound of the formula (1) into another compound of the formula (1);
- ii) removing any protecting groups; or
- iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.